Key clinical point: Subcutaneous daratumumab in combination with standard care produced response rates that are comparable to those observed with intravenous daratumumab plus standard care in patients with newly diagnosed or relapsed/refractory multiple myeloma.
Major finding: The overall response rate (ORR) was 97% with subcutaneous daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-eligible, newly diagnosed patients. The ORR was 89.6% with subcutaneous daratumumab plus bortezomib, melphalan, and prednisone in transplant-ineligible, newly diagnosed patients. The ORR was 93.8% with subcutaneous daratumumab plus lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Study details: A phase 2 study of 199 patients.
Disclosures: The trial was sponsored by Janssen Research & Development. Dr. Chari reported relationships with Janssen and several other companies.
Chari A et al. IMW 2019, Abstract OAB-022.